ArticleNeurology(R) neuroimmunology & neuroinflammation2021

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.

Martin S Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.